Related Experiment Video
Updated: Dec 27, 2025
06:48
Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
Published on: March 23, 2022
2.7K
Glanzmann thrombasthenia: genetic basis and clinical correlates
Juliana Perez Botero1, Kristy Lee2, Brian R Branchford3
1Versiti and Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Haematologica
|March 7, 2020
Summary
Glanzmann thrombasthenia (GT) is a rare genetic bleeding disorder affecting platelet aggregation due to integrin defects. Early diagnosis and multidisciplinary care are crucial for managing severe bleeding complications.
Area of Science:
- Hematology
- Genetics
- Molecular Biology
Background:
- Glanzmann thrombasthenia (GT) is an autosomal recessive platelet aggregation disorder.
- It stems from quantitative or qualitative defects in αIIb and β3 integrins, crucial for fibrinogen binding.
- These integrins form the platelet glycoprotein (GP)IIb/IIIa complex, essential for hemostasis.
Purpose of the Study:
- To review the clinical and molecular aspects of Glanzmann thrombasthenia.
- To emphasize the importance of multidisciplinary care in managing GT patients.
- To highlight challenges in treating GT, including pregnancy-related complications.
Main Methods:
- Review of clinical and molecular data related to Glanzmann thrombasthenia.
- Analysis of diagnostic criteria, including platelet aggregation and glycoprotein expression studies.
- Evaluation of current management strategies and complications.
Main Results:
- GT presents with severe mucocutaneous bleeding, often from early childhood.
- Diagnosis is confirmed by characteristic platelet aggregation patterns and molecular studies.
- Effective management involves hemostatic agents, antifibrinolytics, and sometimes platelet transfusions.
Conclusions:
- Glanzmann thrombasthenia requires a comprehensive approach combining clinical and molecular insights.
- Multidisciplinary care is vital for optimizing patient outcomes and managing complications like alloimmunization.
- Special considerations are necessary for pregnant patients with GT.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
15.2K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.2K
01:24Disorders of Hemostasis
1.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.8K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
226
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
226
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
365
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
365
01:20Extrinsic and Intrinsic Pathways of Hemostasis
11.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.5K